Leif Bertilsson
Leif Bertilsson
Dirección de correo verificada de ki.se
Título
Citado por
Citado por
Año
" Serotonin depression"--a biochemical subgroup within the affective disorders?
M Asberg, P Thoren, L Traskman, L Bertilsson, V Ringberger
Science 191 (4226), 478-480, 1976
8851976
Monoamine metabolites in CSF and suicidal behavior
L Träskman, M Åsberg, L Bertilsson, L Sjüstrand
Archives of general psychiatry 38 (6), 631-636, 1981
8331981
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim, C Risinger, ML Dahl, E Aklillu, M Christensen, L Bertilsson, ...
Clinical Pharmacology & Therapeutics 79 (1), 103-113, 2006
8122006
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
I Johansson, E Lundqvist, L Bertilsson, ML Dahl, F Sjöqvist, ...
Proceedings of the National Academy of Sciences 90 (24), 11825-11829, 1993
7911993
Clomipramine treatment of obsessive-compulsive disorder: II. Biochemical aspects.
P Thoren, M Åsberg, L Bertilsson, B Mellström, F Sjöqvist, L Träskman
Archives of general psychiatry, 1980
7841980
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
L Bertilsson, ML Dahl, P Dalén, A Al‐Shurbaji
British journal of clinical pharmacology 53 (2), 111-122, 2002
6242002
Geographical/interracial differences in polymorphic drug oxidation
L Bertilsson
Clinical pharmacokinetics 29 (3), 192-209, 1995
6061995
Loss of heterozygosity on 10q23. 3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial …
N Sato, H Tsunoda, M Nishida, Y Morishita, Y Takimoto, T Kubo, ...
Cancer research 60 (24), 7052-7056, 2000
5562000
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
I Johansson, M Oscarson, QY Yue, L Bertilsson, F Sjöqvist, ...
Molecular pharmacology 46 (3), 452-459, 1994
5461994
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin
L Bertilsson, YQ Lou, YL Du, Y Liu, TY Kuang, XM Liao, KY Wang, ...
Clinical Pharmacology & Therapeutics 51 (4), 388-397, 1992
4921992
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
E Aklillu, I Persson, L Bertilsson, I Johansson, F Rodrigues, ...
Journal of pharmacology and experimental therapeutics 278 (1), 441-446, 1996
4881996
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
ML Dahl, I Johansson, L Bertilsson, M Ingelman-Sundberg, F Sjöqvist
Journal of Pharmacology and Experimental Therapeutics 274 (1), 516-520, 1995
4211995
Homicide, suicide and CSF 5‐HIAA
L Lidberg, JR Tuck, M Åsberg, GP Scalia‐Tomba, L Bertilsson
Acta Psychiatrica Scandinavica 71 (3), 230-236, 1985
3851985
10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
P Dalén, ML Dahl, MLB Ruiz, J Nordin, L Bertilsson
Clinical Pharmacology & Therapeutics 63 (4), 444-452, 1998
3681998
CSF monoamine metabolites in melancholia
M Åsberg, L Bertilsson, B Mårtensson, GP Scalia‐Tomba, P Thoren, ...
Acta Psychiatrica Scandinavica 69 (3), 201-219, 1984
3591984
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
L Bertilsson, JA Carrillo, ML Dahl, A Llerena, C Alm, U Bondesson, ...
British journal of clinical pharmacology 38 (5), 471-473, 1994
3531994
Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide
L Bertilsson, T Tomson
Clinical pharmacokinetics 11 (3), 177-198, 1986
3491986
CSF 5‐HIAA predicts suicide risk after attempted suicide
P Nordström, M Samuelsson, M Åsberg, L Träskman‐Bendz, ...
Suicide and Life‐Threatening Behavior 24 (1), 1-9, 1994
3131994
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.
M Jerling, L Lindström, U Bondesson, L Bertilsson
Therapeutic drug monitoring 16 (4), 368-374, 1994
3041994
Clinical pharmacokinetics of carbamazepine
L Bertilsson
Clinical pharmacokinetics 3 (2), 128-143, 1978
3031978
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20